What is the recommended workup and treatment for a patient with a history of seizures?

Workup and Treatment for History of Seizures

For patients with a history of seizures presenting to the emergency department, initiate benzodiazepines immediately for active seizures, followed by second-line agents (levetiracetam, fosphenytoin, or valproate) if seizures persist despite optimal benzodiazepine dosing—all three agents show similar efficacy. 1

Initial Assessment and Workup

History and Physical Examination

Focus on identifying:

• Seizure characteristics: Duration, frequency, type (generalized vs focal), presence of aura, postictal confusion
• Witness accounts and smartphone videos: Critical for distinguishing true seizures from mimics 2
• Specific features with diagnostic value: Cyanosis, hypersalivation, tongue biting, postictal disorientation 3
• Provoking factors: Sleep deprivation, medication noncompliance, alcohol withdrawal, metabolic derangements
• Red flags: New-onset seizures in adults warrant neuroimaging to exclude structural lesions 4

Laboratory Studies

• Glucose level: Check immediately to exclude hypoglycemia 5
• Electrolytes: Sodium, calcium, magnesium to identify metabolic causes 5
• Antiepileptic drug levels: If patient on chronic therapy, assess compliance
• Toxicology screen: Only if clinical suspicion for toxic/metabolic encephalopathy 3
• Prolactin level: Obtain 10-20 minutes post-event to differentiate true seizures from psychogenic events 3

Neuroimaging

• MRI brain with epilepsy protocol: Preferred imaging modality including thin-cut coronal slices 6
• CT head: Acceptable in emergency setting when structural lesion suspected or etiology unknown 3
• Timing: New-onset seizures in cancer patients or worsening seizure disorder in brain tumor patients should trigger immediate MRI 4

Electroencephalography (EEG)

• Timing: Perform within 24 hours after seizure, particularly in children 3
• Sleep EEG: Recommended if waking EEG is normal 3
• Continuous EEG monitoring: Essential to rule out nonconvulsive status epilepticus in patients with altered mental status or vigilance problems 4

Acute Management

Status Epilepticus Treatment Algorithm

First-Line: Benzodiazepines

• Lorazepam 0.1 mg/kg IV (maximum 4 mg per dose) 5
• Repeat after 5 minutes if seizures continue
• Maximum 4 doses total

Second-Line Agents (if benzodiazepines fail) 1

The 2024 ACEP guidelines based on the ESETT trial (Class I evidence) demonstrate equal efficacy among three options:

1. Levetiracetam: 60 mg/kg IV (maximum 4,500 mg) at 100 mg/min

   • Advantages: Fewer cardiovascular side effects (0.7% hypotension), no drug interactions 1
   • Disadvantages: Psychiatric side effects possible 4

2. Fosphenytoin: 20 PE/kg IV at 150 mg/min

   • Advantages: Traditional agent with established efficacy
   • Disadvantages: 3.2% hypotension rate, cardiac dysrhythmias, drug interactions 1

3. Valproate: 40 mg/kg IV (maximum 3,000 mg) at 10 mg/kg/min

   • Advantages: Can be given rapidly, 88% efficacy, minimal hypotension 5
   • Disadvantages: Contraindicated in pregnancy, liver toxicity risk, thrombocytopenia 5

Critical Point: The ESETT trial showed cessation of seizure activity occurred in approximately 47-45% across all three groups with no significant differences 1. Choose based on patient-specific factors (pregnancy status, liver disease, psychiatric history, cardiovascular stability).

Third-Line Agents (refractory status epilepticus)

• Propofol: 2 mg/kg bolus, then 5 mg/kg/hour infusion (requires intubation) 5
• Phenobarbital: 10-20 mg/kg IV load (respiratory depression risk) 5
• Pentobarbital: For cases refractory to above agents 5

Long-Term Management

Antiepileptic Drug Selection

First-line agents 4:

• Levetiracetam: Drug of first choice at most centers; avoid enzyme-inducing agents (phenytoin, carbamazepine, phenobarbital) due to drug interactions with steroids and chemotherapy 4
• Lamotrigine: Good efficacy but requires weeks to reach therapeutic levels 4
• Valproic acid: Effective but contraindicated in women of childbearing potential 4

Special Populations

Brain Tumor Patients 4:

• No primary prophylaxis indicated (Level I, D recommendation)
• Secondary prophylaxis: Required after first seizure until local tumor control achieved
• Tapering: Consider stopping ASMs weeks after gross total resection if no recurrence
• Avoid enzyme-inducing anticonvulsants due to interactions with chemotherapy

Traumatic Brain Injury 7:

• ASM prophylaxis may be used but is not mandatory (weak recommendation)
• If used: Levetiracetam preferred over phenytoin
• Duration: ≤7 days only (longer duration associated with worse cognitive outcomes)

Monitoring and Follow-Up

• Serum drug levels: Check for compliance assessment and dose optimization 4
• Seizure diary: Document frequency and characteristics
• Driving restrictions: Adhere to local laws regarding seizure-free intervals 4
• Psychiatric comorbidities: Screen and treat anxiety, depression 2

Common Pitfalls

1. Avoid prolonged ASM prophylaxis: No benefit beyond 7 days in TBI; increases adverse events 7
2. Don't use enzyme-inducers in cancer patients: Phenytoin, carbamazepine, phenobarbital interact with chemotherapy 4
3. Don't delay second-line agents: Administer immediately if benzodiazepines fail; all three options equally effective 1
4. Don't prescribe ASMs for functional seizures: No evidence of benefit; focus on psychological interventions 2
5. Don't assume compliance: Check drug levels in breakthrough seizures before escalating therapy 4